A new doctoral study from Sweden's Karolinska Institutet has found that sexual difficulties are common among young people who have survived cancer treatment. The nature and severity of those difficulties shift considerably based on cancer type and how intensively the patient was treated. Charlotta Bergström, a nurse and doctoral student at the Karolinska Institutet, led the research, which covered more than 1,000 patients.
As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) continue with their efforts geared toward developing the next generation of medications indicated for brain cancer, there is hope that the treatments they commercialize could have a better safety profile and fewer side effects impacting the quality of life for survivors. The study's findings highlight the need for improved follow-up care and support for young adults after cancer treatment.
The research underscores the importance of considering long-term side effects when developing new cancer therapies. While the study did not specify which treatments were associated with the most sexual difficulties, it emphasizes that healthcare providers should discuss potential sexual health issues with patients before and after treatment. The findings also suggest that more research is needed to understand the mechanisms behind these problems and to develop interventions to mitigate them.
For more information about the study, please visit the Karolinska Institutet website. The study is part of a growing body of evidence that cancer treatments can have lasting effects on sexual function, which is an important aspect of overall well-being for survivors.
